Candesartan
As of the edition of 20 October 2026, Candesartan is a small molecule: marketed, first approved in 1997 (CH); acts on AGTR1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Small molecule
- Brand name
- Atacand
- First approved
- 26 August 1997 (CH)
- Approvals on record
- 7 in 3 regions
- Holder of the most recent approval
- BIOPAS BRASIL PRODUTOS FARMACEUTICOS LTDA; 4 holders in all
- Registered trials
- 65, 9 stopped early
- Disease areas
- Heart and blood vessels; Nutrition and metabolism; Nervous system; Hormones; Urinary and reproductive; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Candesartan.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| AGTR1 | Type-1 angiotensin II receptor | P30556 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 11 | 8 | 1 | 0 |
| Phase 1 | 15 | 12 | 1 | 1 |
| Phase 2 | 8 | 5 | 0 | 1 |
| Phase 3 | 16 | 7 | 3 | 4 |
| Phase 4 | 15 | 7 | 0 | 3 |
| All trials | 65 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AstraZeneca | Applicant and Lead sponsor of trials | 2001 to now |